The Lancet DECEMBER 03, 2016

Nordic–Baltic–British Left Main Revascularisation (NOBLE) Trial

Timo Mäkikallio, Niels R. Holm, Mitchell Lindsay, et al. (NOBLE Study Investigators)

Bottom Line

The NOBLE trial demonstrated that percutaneous coronary intervention (PCI) with drug-eluting stents was inferior to coronary artery bypass grafting (CABG) regarding 5-year clinical outcomes in patients with unprotected left main coronary artery disease, driven largely by higher rates of non-procedural myocardial infarction and repeat revascularization.

Key Findings

1. At 5 years, the primary endpoint of major adverse cardiac or cerebrovascular events (MACCE)—a composite of all-cause mortality, non-procedural myocardial infarction, repeat revascularization, and stroke—occurred in 28% of the PCI group compared to 19% in the CABG group (Hazard Ratio 1.58; 95% CI 1.24–2.01; p=0.0002), failing to meet the criterion for non-inferiority.

2. Individual components at 5 years highlighted significantly higher rates of non-procedural myocardial infarction (8% vs. 3%; HR 2.99) and repeat revascularization (17% vs. 10%; HR 1.73) in the PCI group.

3. All-cause mortality at 5 years was similar between groups (9% for both; p=0.68).

4. Long-term follow-up at 10 years confirmed similar all-cause mortality between the two treatment strategies (23% in PCI vs. 25% in CABG; p=0.56), though a subgroup analysis suggested a potential mortality benefit for PCI in patients presenting with acute coronary syndrome.

5. PCI was associated with lower 30-day morbidity compared to CABG, including shorter hospital stays, fewer reoperations for bleeding, and lower transfusion requirements.

Study Design

Design

RCT

Open-Label

Sample

1,184

Patients

Duration

5 yr

Median

Setting

Multicenter, Europe

Population Patients with unprotected left main coronary artery disease (stenosis diameter ≥50% or FFR ≤0.80) considered eligible for either PCI or CABG by a Heart Team.

Intervention Percutaneous coronary intervention (PCI) using drug-eluting stents.

Comparator Coronary artery bypass grafting (CABG).

Outcome Major adverse cardiac or cerebrovascular events (MACCE), defined as a composite of all-cause mortality, non-procedural myocardial infarction, repeat revascularization, and stroke.

Study Limitations

• The study was open-label, which may introduce ascertainment bias in reporting non-fatal events.

• The trial was originally designed with a specific number of events to power the non-inferiority hypothesis; the relatively slow accrual of events and subsequent protocol adjustments may affect the precision of the findings.

• The definition of the primary endpoint included repeat revascularization, which inherently inflates the event rate for PCI compared to CABG, impacting the comparative assessment of clinical superiority.

• The study enrolled a population with a relatively low average SYNTAX score (median 22.5), which may limit the generalizability of these findings to patients with more complex, high-risk anatomy.

Clinical Significance

The NOBLE trial challenges the interchangeability of PCI and CABG for unprotected left main disease, emphasizing that while PCI offers immediate procedural benefits and reduced early morbidity, CABG remains the superior revascularization strategy for minimizing long-term non-procedural myocardial infarction and the need for subsequent revascularization. This underscores the importance of Heart Team evaluation in determining the optimal long-term strategy for complex coronary disease.

Historical Context

Historically, CABG was considered the gold standard for unprotected left main disease. The NOBLE trial was initiated during a period of rapid advancement in drug-eluting stent technology to evaluate if PCI could be a valid non-inferior alternative, providing a critical counterpoint to the larger EXCEL trial and contributing to ongoing global debates regarding revascularization choices.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

Given that the left main coronary artery (LMCA) provides the primary blood supply to the left ventricle, what is the physiological rationale for why CABG might provide more durable protection against future myocardial infarction compared to PCI in this specific location?

Key Response

CABG involves placing conduits (like the Internal Mammary Artery) distal to the entire proximal diseased segment, 'bypassing' potential future 'de novo' lesions in the proximal vessels. In contrast, PCI only treats the focal stenotic lesion. Because LMCA disease is often a marker for aggressive, widespread atherosclerosis, the 'surgical protection' of distal segments reduces the risk of MI arising from new proximal disease progression.

Resident

In a patient with unprotected left main disease and a SYNTAX score of 25, how do the results of the NOBLE trial guide your recommendation between PCI and CABG?

Key Response

The NOBLE trial found PCI to be clinically inferior to CABG at 5 years, with a higher rate of non-procedural MI and repeat revascularization. For a patient with an intermediate SYNTAX score (23-32), CABG is generally preferred (Class 1 recommendation) because PCI outcomes in NOBLE showed significantly higher rates of Major Adverse Cardiac and Cerebrovascular Events (MACCE) compared to the surgical cohort.

Fellow

The NOBLE and EXCEL trials reached different conclusions regarding the non-inferiority of PCI for left main disease. How did the specific definition of myocardial infarction (MI) used in NOBLE influence its primary endpoint compared to the EXCEL trial?

Key Response

EXCEL used a biomarker-based definition (CK-MB elevation) which captured many peri-procedural MIs (more common in CABG), potentially masking PCI's long-term risks. NOBLE used a clinical definition (Universal Definition of MI) excluding small peri-procedural enzyme leaks. This approach highlighted a higher rate of spontaneous (non-procedural) MIs in the PCI arm during follow-up, contributing to the finding of PCI inferiority.

Attending

How should the 5-year NOBLE data influence the 'Heart Team' discussion for a relatively young patient (e.g., age 55) with low anatomical complexity (SYNTAX <22) who is hesitant about the recovery time of surgery?

Key Response

The attending must emphasize that while PCI offers faster recovery, NOBLE demonstrates that the 'price' of PCI in the left main is a significantly higher risk of repeat procedures and spontaneous MI over 5 years. For a younger patient with a long life expectancy, the long-term durability and 'vessel-wide' protection of CABG likely outweigh the short-term benefits of a percutaneous approach.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

Critique the use of a composite primary endpoint in NOBLE (death, MI, stroke, or repeat revascularization) from a statistical power perspective, specifically regarding the inclusion of repeat revascularization.

Key Response

Repeat revascularization is a 'soft' endpoint compared to death or MI and is often the primary driver of event rates in PCI trials. Including it increases the power to find a difference but can dilute the importance of 'hard' clinical outcomes. In NOBLE, the inclusion of revascularization clearly separated the curves, but researchers must ensure that the treatment effect on the 'soft' component doesn't mask a null or opposite effect on the 'hard' components.

Journal Editor

A significant portion of the PCI cohort in NOBLE received first-generation Biolimus-eluting stents rather than the current standard-of-care cobalt-chromium everolimus-eluting stents. To what extent does this 'technological lag' threaten the external validity of the trial in today's clinical landscape?

Key Response

Editors look for 'obsolescence' bias. If the stents used in the trial are no longer used or are inferior to current generation stents, the trial may overestimate the hazards of PCI. However, subsequent sub-analyses often suggest that the fundamental issues of PCI in the left main (incomplete revascularization and ostial/bifurcation recoil) persist regardless of the specific drug-eluting stent generation used.

Guideline Committee

Based on the 5-year results of NOBLE and the subsequent 2021 ACC/AHA/SCAI guidelines, should the recommendation for PCI in left main disease be downgraded for patients with low-to-intermediate anatomical complexity?

Key Response

Current guidelines (ACC/AHA 2021) maintain a Class 2a recommendation for PCI in select LMCA patients (low SYNTAX score). However, NOBLE’s findings of higher non-procedural MI rates in the PCI arm provide strong evidence for the Committee to emphasize CABG as the preferred standard (Class 1) and to suggest PCI only for patients who are poor surgical candidates or who explicitly prioritize short-term recovery over long-term durability.

Clinical Landscape

Noteworthy Related Trials

2009

SYNTAX Trial

n = 1,800 · NEJM

Tested

Paclitaxel-eluting stents (PCI)

Population

Patients with de novo three-vessel disease or left main coronary artery disease

Comparator

Coronary-artery bypass grafting (CABG)

Endpoint

Major adverse cardiac or cerebrovascular events (MACCE) at 12 months

Key result: CABG remains the standard of care for patients with complex three-vessel or left main coronary disease due to higher rates of repeat revascularization with PCI.

2011

PRECOMBAT Trial

n = 600 · NEJM

Tested

Sirolimus-eluting stents (PCI)

Population

Patients with unprotected left main coronary artery disease

Comparator

Coronary-artery bypass grafting (CABG)

Endpoint

Composite of death, myocardial infarction, or stroke at 12 months

Key result: PCI with sirolimus-eluting stents was found to be noninferior to CABG for major cardiac and cerebrovascular events at 1 year.

2016

EXCEL Trial

n = 1,905 · NEJM

Tested

Everolimus-eluting stents (PCI)

Population

Patients with unprotected left main coronary artery disease

Comparator

Coronary-artery bypass grafting (CABG)

Endpoint

Composite of death, stroke, or myocardial infarction at 3 years

Key result: PCI was noninferior to CABG with respect to the primary endpoint at 3 years.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis